Firma immatics biotechnologies, Autor bei News-Research

Immatics weitet klinisches Studienprogramm für adoptive Zelltherapien auf Europa aus

18. August 2020 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged actengine, aussagen, cancer, ima200, ima202, ima203, immatics, patienten, pei, tcr, tcrs, ucc, upmc, uthealth

Der erste Patient in Deutschland wurde im Rahmen der Immatics‘ ACTengine® IMA202-101 Studie behandelt Die deutsche Zulassungsbehörde, das Paul-Ehrlich-Institut (PEI), hat den Antrag (CTA, Clinical Trial Application) für eine weitere […]

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs

18. August 2020 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged ??forward, cancer, ima201, ima202, ima203, immatics, looking, patients, pei, securities, statements, tcr, ucc, uthealth

First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial German regulatory agency, Paul-Ehrlich-Institute (PEI), granted approval to commence another clinical ACTengine® trial in Germany investigating Immatics’ IMA203 […]

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth

6. August 2020 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged actallo, actengine, cancer, cell, cells, dentistry, griffin, immatics, patients, research, securities, statements, tcr, uthealth, with

. Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP manufacturing infrastructure at The Evelyn H. Griffin Stem Cell Therapeutics […]

Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ

9. Juli 2020 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged attack, cancer, cell, chambr, clinical, discovery, financial, immatics, immunotherapies, new, patients, securities, statements, tcr, with

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced changes to its Board of Directors in conjunction […]

Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

30. Juni 2020 Firma immatics biotechnologiesPosted in Kooperationen / FusionenTagged arya, aryas, cancer, cell, cells, cms, immatics, patients, perceptive, power, securities, statements, svb, tcr, with

Arya Sciences Acquisition Corp. (NASDAQ: ARYA or “Arya”), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery […]

Immatics Appoints Cedrik Britten as Chief Medical Officer

4. Juni 2020 Firma immatics biotechnologiesPosted in AllgemeinTagged biontech, cancer, cell, clinical, financial, immatics, immunotherapies, immunotherapy, new, patients, research, statements, tcr, therapy, with

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that Cedrik Britten, MD, has been appointed as Chief […]